Vericel (NASDAQ:VCEL) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Vericel Co. (NASDAQ:VCEL) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $50.40 and traded as high as $58.01. Vericel shares last traded at $57.43, with a volume of 376,137 shares.

Wall Street Analyst Weigh In

VCEL has been the subject of several recent analyst reports. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Stephens reissued an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial boosted their target price on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, BTIG Research raised their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.14.

Vericel Price Performance

The company has a market cap of $2.83 billion, a P/E ratio of 957.33 and a beta of 1.72. The company’s 50-day moving average is $57.40 and its two-hundred day moving average is $50.47.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Equities research analysts anticipate that Vericel Co. will post 0.12 EPS for the current year.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total transaction of $587,200.00. Following the transaction, the insider now owns 58,371 shares of the company’s stock, valued at $3,427,545.12. This represents a 14.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,100 shares of company stock valued at $889,872 in the last 90 days. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Vericel

A number of large investors have recently modified their holdings of VCEL. Mirae Asset Global Investments Co. Ltd. increased its stake in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the period. Farther Finance Advisors LLC raised its holdings in Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares in the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in shares of Vericel by 1.1% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 43,781 shares of the biotechnology company’s stock valued at $2,404,000 after buying an additional 489 shares during the period. PFG Investments LLC grew its stake in shares of Vericel by 8.0% during the 3rd quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 550 shares during the period. Finally, International Assets Investment Management LLC increased its position in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.